Peter P. Lee
Publications
- Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med. 2011; (1): 122
- Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011: 52
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res. 2011; (10): 3064-76
- T cell state transition produces an emergent change detector. J Theor Biol. 2011; (1): 59-69
- Quantitative, architectural analysis of immune cell subsets in tumor-draining lymph nodes from breast cancer patients and healthy lymph nodes. PLoS One. 2010; (8): e12420
- An Interactive Java Statistical Image Segmentation System: GemIdent. J Stat Softw. 2009; (10)
- Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Oncol Res. 2009; (5-6): 287-92
- Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009; (22): 9010-5
- Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood. 2008; (11): 5342-9
- Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol. 2008; (15): 4626-35
- Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models. Bull Math Biol. 2008; (3): 728-44
- Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007; (5): e176
- Gene expression network analysis and applications to immunology. Bioinformatics. 2007; (7): 850-8
- Modeling regulation mechanisms in the immune system. J Theor Biol. 2007; (1): 33-69
- Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother. 2006; (10): 3250-9
- Rational design of combination enzyme therapy for celiac sprue. Chem Biol. 2006; (6): 649-58
- Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J Immunother. 2005 Jul-Aug; (4): 297-305
- Agent-based modeling of the context dependency in T cell recognition. J Theor Biol. 2005; (4): 376-91
- Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med. 2005; (10): e265
- Memory T cells have gene expression patterns intermediate between naive and effector. Proc Natl Acad Sci U S A. 2005; (15): 5519-23
- Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. J Theor Biol. 2005; (1): 39-59
- Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005; (9): e284
- Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004; (2): e28
- Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res. 2004; (10): 3661-7
- T-cell responses to cancer. Methods Cell Biol. 2004: 513-32
- A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. 2003; (4): 1301-12
- Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003; (5): 639-47
- Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med. 2003; (11): 1377-82
- Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2003; (1): 186-200
- Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A. 2003; (20): 11672-7
- Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002 Mar-Apr; (2): 97-138
- A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002; (4): 1021-32
- Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation. 2002; (4): 501-10
- A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001; (2): 243-51
- Effects of Interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma Journal of Clinical Oncology. 2001
- Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000; (9): 1018-23
- Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000; (11): 1637-44
- The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol. 2000; (2): 596-602
- A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999; (11): 2675-81
- Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999; (6): 677-85
- Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999; (4): 2227-34
- T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood. 1997; (4): 1611-7
- An oligonucleotide blocks interferon-gamma signal transduction. Transplantation. 1996; (9): 1297-301
- Pharmacokinetics of 111In-labelled monoclonal antibody ZCE-025 and fragments in tumour-bearing mice. Nucl Med Commun. 1995; (4): 299-305
- Origin of regional and species differences in intestinal glucose uptake. Am J Physiol. 1989; (5 Pt 1): G689-97
Help
Trial Administration